Ximena Barbadora

Dr. Ximena Barbadora

URV
+1
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
XBXimena Barbadora
Ximena Barbadora
GMGemma Montagut
Gemma Montagut
MBMario Bustos
Mario Bustos
NLNiurka Llopiz
Niurka Llopiz
Anna Ardévol GrauAnna Ardévol Grau
Anna Ardévol Grau
M Teresa BlayM Teresa Blay
M Teresa Blay

27 April 2007 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
XBXimena Barbadora
Ximena Barbadora
JFJosep Valls Fonayet
Josep Valls Fonayet
XVXavier Vitrac
Xavier Vitrac
JMJean-Michel Mérrillon
Jean-Michel Mérrillon
Lluís ArolaLluís Arola
Lluís Arola
M Teresa BlayM Teresa Blay
M Teresa Blay

14 November 2016 in Nutrition Research Reviews
Verified
Journal Article
Open access
PDF file
KGKatherine Gil-Cardoso
Katherine Gil-Cardoso
IGIris Ginés
Iris Ginés
MPMontserrat Pinent
Montserrat Pinent
Anna Ardévol GrauAnna Ardévol Grau
Anna Ardévol Grau
M Teresa BlayM Teresa Blay
M Teresa Blay
XBXimena Barbadora
Ximena Barbadora
Diet-induced obesity is associated with low-grade inflammation, which, in most cases, leads to the development of metabolic disorders, primarily insulin resistance and type 2 diabetes. Although prior studies have implicated the adipose tissue as being primarily responsible for obesity-associated inflammation, the latest discoveries have correlated impairments in intestinal immune homeostasis and the mucosal barrier with increased activation of the inflammatory pathways and the development of insulin resistance. Therefore, it is essential to define the mechanisms underlying the obesity-associated gut alterations to develop therapies to prevent and treat obesity and its associated diseases. Flavonoids appear to be promising candidates among the natural preventive treatments that have been identified to date. They have been shown to protect against several diseases, including CVD and various cancers. Furthermore, they have clear anti-inflammatory properties, which have primarily been evaluated in non-intestinal models. At present, a growing body of evidence suggests that flavonoids could exert a protective role against obesity-associated pathologies by modulating inflammatory-related cellular events in the intestine and/or the composition of the microbiota populations. The present paper will review the literature to date that has described the protective effects of flavonoids on intestinal inflammation, barrier integrity and gut microbiota in studies conducted using in vivo and in vitro models.

28 April 2011 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
TATeresa Auguet
Teresa Auguet
YQYunuen Quintero
Yunuen Quintero
DRDavid Riesco
David Riesco
BMBeatriz Morancho
Beatriz Morancho
XBXimena Barbadora
Ximena Barbadora
CRCristóbal Richart
Cristóbal Richart
Background: Vaspin and omentin are recently described molecules that belong to the adipokine family and seem to be related to metabolic risk factors. The objectives of this study were twofold: to evaluate vaspin and omentin circulating levels and mRNA expression in subcutaneous and visceral adipose tissues in non-diabetic morbidly obese women; and to assess the relationship of vaspin and omentin with anthropometric and metabolic parameters, and other adipo/cytokines. Design: We analysed vaspin and omentin circulating levels in 71 women of European descent (40 morbidly obese [BMI ≥ 40 kg/m2] and 31 lean [BMI ≤ 25]). We assessed vaspin and omentin gene expression in paired samples of visceral and subcutaneous abdominal adipose tissue from 46 women: 40 morbidly obese and 6 lean. We determined serum vaspin and plasma omentin levels with an Enzyme-Linked Immunosorbent Assay and adipose tissue mRNA expression by real time RT-PCR. Results: Serum vaspin levels in the morbidly obese were not significantly different from those in controls. They correlated inversely with levels of lipocalin 2 and interleukin 6. Vaspin mRNA expression was significantly higher in the morbidly obese, in both subcutaneous and visceral adipose tissue. Plasma omentin levels were significantly lower in the morbidly obese and they correlated inversely with glucidic metabolism parameters. Omentin circulating levels, then, correlated inversely with the metabolic syndrome (MS). Omentin expression in visceral adipose tissue was significantly lower in morbidly obese women than in controls. Conclusions: The present study indicates that vaspin may have a compensatory role in the underlying inflammation of obesity. Decreased omentin circulating levels have a close association with MS in morbidly obese women.

1 April 2011 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
XBXimena Barbadora
Ximena Barbadora
VPVictor Pallarès
Victor Pallarès
Anna Ardévol GrauAnna Ardévol Grau
Anna Ardévol Grau
CBCinta Blade
Cinta Blade
JFJuan Fernández-Larrea
Juan Fernández-Larrea
M Teresa BlayM Teresa Blay
M Teresa Blay

1 April 2011 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
XBXimena Barbadora
Ximena Barbadora
YQYunuen Quintero
Yunuen Quintero
TATeresa Auguet
Teresa Auguet
JPJosé Antonio Porras
José Antonio Porras
MHMercé Hernández
Mercé Hernández
CRCristobal Richart
Cristobal Richart
Objective: The adipocyte/macrophage fatty acid-binding protein 4 (FABP4) has been described as a biomarker for adiposity and metabolic syndrome (MS). The aims of this study were to assess the relationship between FABP4 and inflammatory cytokines related to obesity, and to evaluate FABP4 mRNA expression in visceral and subcutaneous adipose tissue in non-diabetic morbidly obese women versus healthy lean women.Methods: We analyzed circulating levels of FABP4 in 81 Spanish women: 38 lean (body mass index (BMI)40 kg/m2). We took 30 follow-up blood samples at 6 and 12 months after bariatric surgery. We assessed FABP4 gene expression in samples of subcutaneous abdominal and visceral adipose tissue. Adipose tissue mRNA expression was determined by real-time RT-PCR.Results: In morbidly obese women, plasma FABP4 levels were significantly higher than in non-obese patients. These levels positively correlated with BMI, homeostasis model assessment of insulin resistance (HOMA2-IR), and plasma glucose and insulin levels. Post-operative FABP4 levels decreased by a maximum of 30% after 12 months. We also found an inverse association between FABP4 and adiponectin levels, and positive correlations between FABP4 and circulating leptin, tumor necrosis factor (TNF) receptors, C-reactive protein (CRP) and interleukin 6 levels. Linear regression analysis revealed that FABP4 was more closely related to HOMA2-IR than adiponectin, CRP, TNF-RI, or leptin. Furthermore, high circulating FABP4 levels were associated with the presence of MS. FABP4 mRNA expression in visceral adipose tissue was related to its circulating levels in morbidly obese women.Conclusions: Our results indicate that serum FABP4 is associated with inflammatory factors related to obesity and MS in non-diabetic morbidly obese women.